Benzinga | Jun 2, 2021 09:11AM EDT

Butterfly Network Reports Its Second-Generation iQ+ Approved For A Class III Medical Device License In Canada

Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly") announced today that its second-generation iQ+ has been approved for a Class III Medical Device License in Canada. The iQ+ features the world's only Ultrasound-on-Chip(tm) technology, with several hardware and software advances designed to improve usability and care delivery.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005657/en/

Butterfly iQ+ (Photo: Business Wire)

"We are excited that the Butterfly iQ+ will now be available for purchase by Canadian medical professionals," said Todd Fruchterman, MD, Ph.D., President and Chief Executive Officer of Butterfly Network. "Thousands of new practitioners and millions of patients will now have access to a transformative advanced assessment tool that can deliver valuable insights that enable more informed clinical decisions at the point of care."

Innovative technology

Butterfly iQ+ will help unlock the power of medical imaging earlier in the treatment journey with an entire suite of advanced imaging features, such as real-time Biplane Imaging(tm) (the first such feature for a handheld ultrasound device), automatic bladder volume calculation with 3D rendering, Needle Viz(tm) onscreen needle highlighting, and Pulsed Wave Doppler. It includes Educational View Guidance, which helps clinicians improve their scanning technique by providing a visual indication of the quality of the image being collected. Relative to the first-generation device, the iQ+ is built to perform even more reliably throughout demanding shifts with 20% extended battery life and 15% faster frame rates, and has a smaller form factor that allows for tighter control.